Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)(TERMINATED)

Inclusion Criteria:

* Advanced cancer for which there is no treatment available which would have a reasonable chance of disease palliation or cure
* Age greater than or equal to 18.
* SWOG performance Status less than or equal to 2.
* Meets protocol requirements for specified laboratory values.
* Written informed consent and cooperation of patient.

Exclusion Criteria:

* Prior treatment with an FPTI
* Knowledge of intracranial metastases or carcinomatous meningitis.
* Poor medical risks because of nonmalignant systemic disease or uncontrolled active infection.
* Medical conditions that would interfere with taking oral medications.
* Significant uncontrolled diarrhea.
* Chemotherapy, radiotherapy or major surgery within 4 weeks; full recovery from prior treatment.
* Concomitant use of CYP3A inhibitors/inducers per protocol.
* Known HIV positivity or AIDS-related illness.
* Pregnant or nursing women.
* Men or women of childbearing potential who are not using an effective method of contraception.
* Concurrent chemotherapy, hormonal therapy, radiotherapy or immunotherapy.
* QTc prolongation (\>440 msecs) at baseline.
* Patients with previous high-dose therapy requiring stem cell rescue or bone marrow transplant, or irradiation to \>30% of bone marrow-containing areas.
* Patients that have received Mitomycin-C or nitrosoureas.